Abstract:Non-small cell cancer (NSCLC) is the most common cancer in the world, but its effective therapeutic methods are limited. Tilianin and sufentanil alleviate various human tumors. This research aimed to clarify the functions and mechanisms of Tilianin and sufentanil in NSCLC. The functions of Tilianin and sufentanil on NSCLC cell viability, apoptosis, mitochondrial dysfunction, and immunity in vitro were examined using Cell Counting Kit-8 assay, flow cytometry, reactive oxygen species level analysis, CD8+ T cell percentage analysis, Western blot, and enzyme-linked immunosorbent assay, respectively. The molecular mechanism regulated by Tilianin and sufentanil in NSCLC was assessed using Western blot, and immunofluorescence assays. Meanwhile, the roles of Tilianin and sufentanil in NSCLC tumor growth, apoptosis, and immunity in vivo were determined by establishing a tumor xenograft mouse model, immunohistochemistry, and Western blot assays. When sufentanil concentration was proximity 2 nM, the inhibition rate of NSCLC cell viability was 50%. The IC50 for A549 cells was 2.36 nM, and the IC50 for H1299 cells was 2.18 nM. The IC50 of Tilianin for A549 cells was 38.7 μM, and the IC50 of Tilianin for H1299 cells was 44.6 μM. Functionally, 0.5 nM sufentanil and 10 μM Tilianin reduced NSCLC cell (A549 and H1299) viability in a dose-dependent manner. Also, 0.5 nM sufentanil and 10 μM Tilianin enhanced NSCLC cell apoptosis, yet this impact was strengthened after a combination of Tilianin and Sufentanil. Furthermore, 0.5 nM sufentanil and 10 μM Tilianin repressed NSCLC cell mitochondrial dysfunction and immunity, and these impacts were enhanced after a combination of Tilianin and Sufentanil. Mechanistically, 0.5 nM sufentanil and 10 μM Tilianin repressed the NF-κB pathway in NSCLC cells, while this repression was strengthened after a combination of Tilianin and Sufentanil. In vivo experimental data further clarified that 1 µg/kg sufentanil and 10 mg/kg Tilianin reduced NSCLC growth, immunity, and NF-κB pathway-related protein levels, yet these trends were enhanced after a combination of Tilianin and Sufentanil. Tilianin strengthened the antitumor effect of sufentanil in NSCLC.

Sufentanil Suppresses Cell Carcinogenesis Via Targeting miR-186-5p/HMGB1 Axis and Wnt/β-Catenin Pathway in Non-Small-Cell Lung Cancer

MiR-195 suppresses non-small cell lung cancer by targeting CHEK1.

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Microrna-187 Inhibits Pten Expression And Promotes Cell Proliferation In Non-Small-Cell Lung Cancer

MiRNA-20b/SUFU/Wnt Axis Accelerates Gastric Cancer Cell Proliferation, Migration and EMT

Tilianin enhances the antitumor effect of sufentanil on non-small cell lung cancer

Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer

miR-489-3p promotes malignant progression of non-small cell lung cancer through the inactivation of Wnt/β-catenin signaling pathway via regulating USP48

Epigenetic Silencing of Mir-218 by the Lncrna CCAT1, Acting Via BMI1, Promotes an Altered Cell Cycle Transition in the Malignant Transformation of HBE Cells Induced by Cigarette Smoke Extract.

miR-146a-5p Plays an Oncogenic Role in NSCLC via Suppression of TRAF6

CXCL6 Promotes Non-Small Cell Lung Cancer Cell Survival and Metastasis Via Down-Regulation of Mir-515-5p

Mir‑146a‑5p Targets TCSF and Influences Cell Growth and Apoptosis to Repress NSCLC Progression

SUFU mediates EMT and Wnt/β-catenin signaling pathway activation promoted by miRNA-324-5p in human gastric cancer.

SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1

Inhibition of Mir‑194 Suppresses the Wnt/β‑catenin Signalling Pathway in Gastric Cancer.

Dual activation of Hedgehog and Wnt/β-catenin signaling pathway caused by downregulation of SUFU targeted by miRNA-150 in human gastric cancer

Suppression of CX3CL1 by miR-497-5p inhibits cell growth and invasion through inactivating the ERK/AKT pathway in NSCLC cells

MicroRNA-200a Suppresses Migration and Invasion and Enhances the Radiosensitivity of NSCLC Cells by Inhibiting the HGF/c-Met Signaling Pathway

MiR-216b/Smad3/BCL-2 Axis Is Involved in Smoking-Mediated Drug Resistance in Non-Small Cell Lung Cancer

Downregulation of Microrna-196A Enhances the Sensitivity of Non-Small Cell Lung Cancer Cells to Cisplatin Treatment

Retraction Note: Dual Roles of Mir-374A by Modulated C-Jun Respectively Targets CCND1-inducing PI3K/AKT Signal and PTEN-suppressing Wnt/β-catenin Signaling in Non-Small-cell Lung Cancer.